Analysts Set Expectations for RCKT FY2026 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Rocket Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the biotechnology company will post earnings per share of ($1.66) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $30.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share.

A number of other brokerages have also issued reports on RCKT. Evercore ISI lowered Rocket Pharmaceuticals from an "outperform" rating to an "in-line" rating and set a $5.00 target price on the stock. in a research report on Friday, May 30th. Leerink Partnrs downgraded shares of Rocket Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 27th. Wedbush reissued an "outperform" rating and set a $32.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, May 16th. Chardan Capital cut their price objective on Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 28th. Finally, UBS Group restated a "buy" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Rocket Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $19.57.

Rocket Pharmaceuticals Price Performance

RCKT stock traded down $0.14 during mid-day trading on Tuesday, reaching $2.93. 3,106,677 shares of the company's stock were exchanged, compared to its average volume of 2,052,094. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals has a 12-month low of $2.19 and a 12-month high of $26.98. The stock's 50 day moving average is $5.55 and its 200 day moving average is $8.73. The company has a market cap of $312.88 million, a price-to-earnings ratio of -1.07 and a beta of 0.68.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same quarter in the previous year, the business earned ($0.66) EPS.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Several large investors have recently made changes to their positions in RCKT. Wellington Management Group LLP increased its holdings in Rocket Pharmaceuticals by 24.5% in the 4th quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company's stock valued at $175,919,000 after purchasing an additional 2,753,033 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Rocket Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 6,617,784 shares of the biotechnology company's stock worth $44,141,000 after buying an additional 40,189 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Rocket Pharmaceuticals by 2.3% in the first quarter. Westfield Capital Management Co. LP now owns 4,820,701 shares of the biotechnology company's stock valued at $32,154,000 after buying an additional 106,091 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Rocket Pharmaceuticals by 111.0% in the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company's stock valued at $50,343,000 after buying an additional 2,106,699 shares in the last quarter. Finally, Suvretta Capital Management LLC purchased a new stake in shares of Rocket Pharmaceuticals in the 4th quarter valued at $32,267,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Kinnari Patel bought 21,099 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $4.70 per share, with a total value of $99,165.30. Following the completion of the transaction, the insider now directly owns 26,774 shares of the company's stock, valued at $125,837.80. This represents a 371.79% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now owns 129,650 shares of the company's stock, valued at approximately $685,848.50. This represents a 5.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 24.76% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.